Filed Pursuant to Rule 424(b)(3)
                                                Registration No. 333-109070


                               CEL-SCI CORPORATION

                              Prospectus Supplement
                     (To Prospectus Dated February 11, 2005)

     Prospective  investors  should  read  this  prospectus  supplement  and the
related  prospectus  carefully before investing in CEL-SCI's common stock.  Both
documents contain information  prospective investors should consider when making
an investment decision.

     The attached prospectus relates to the resale of shares acquired by Rubicon
Group Ltd. pursuant to an equity line of credit.  Because Rubicon Group Ltd. may
sell some or all of these shares,  and since there are currently no  agreements,
arrangements or understandings  with respect to the sale of any of these shares,
CEL-SCI cannot  estimate the actual number of shares that Rubicon Ltd. will hold
after the completion of the offering.

     The following provides information concerning the latest drawdown requested
by CEL-SCI under the equity line of credit.

      Date of          Shares       Average Sale    Net Proceeds
        Sale            Sold       Price Per Share   to CEL-SCI
      -------          ------      ---------------  ------------

       6-2-05          87,303          $0.57           $50,000


     CEL-SCI's  common stock is quoted on the American  Stock Exchange under the
symbol  "CVM".  On June 1, 2005 the  closing  price  for one share of  CEL-SCI's
common stock was $0.69.

     CEL-SCI  expects  to use the  proceeds  from the sale of these  shares  for
general and administrative expenses, research and clinical trials.












             The date of this prospectus supplement is June 2, 2005.